Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
TGR-1202 (formerly RP5264)
print preview
bookmark
share with colleague
General Information
Company
Rhizen Pharmaceuticals S.A.
Description
Phosphoinositide 3-kinase (PI3K) delta inhibitor
Molecular Target
Phosphoinositide 3-kinase (PI3K) delta
Mechanism of Action
Phosphoinositide 3-kinase (PI3K) delta inhibitor
Latest Stage of Development
Phase I
Indication
B cell lymphoma
Partner
TG Therapeutics Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy